So far as our Directors are aware, immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised and no Shares will be issued under the ESOPs), the following persons will have an interest or short position in the Shares or the underlying Shares of our Company which would fall to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the issued voting shares of our Company:

		Immediately following the completion of the [REDACTED]	
Name of Shareholder	**Nature of Interest**[1]	**Number of Shares**	**Shareholding**
Sanaron	Beneficial owner	[**REDACTED**]	[**REDACTED**]
Radiant Harbour	Interest in controlled corporation[2]	[**REDACTED**]	[**REDACTED**]
Trident Trust Company (HK) Limited	Trustee of trust[2]	[**REDACTED**]	[**REDACTED**]
Dr. Wu	Founder of trust and interest in controlled corporation[2]	[**REDACTED**]	[**REDACTED**]
	Beneficial owner[3]	[**REDACTED**]	[**REDACTED**]
Ms. Jin	Advisor of trust and interest of spouse[2]	[**REDACTED**]	[**REDACTED**]
	Interest of spouse[3]	[**REDACTED**]	[**REDACTED**]
FIIF Overseas Investment (BVI) Co., Limited	Beneficial owner	[**REDACTED**]	[**REDACTED**]
Future Industry Investment Fund (Limited Partnership) (先進製造產業投資基金(有限合夥))	Interest in controlled corporation[4]	[**REDACTED**]	[**REDACTED**]
SDIC Fund Management Co., Ltd. (國投創新投資管理有限公司)	Interest in controlled corporation[4]	[**REDACTED**]	[**REDACTED**]
Decheng Capital China Life Sciences USD Fund II, L.P.	Beneficial owner	[**REDACTED**]	[**REDACTED**]
Decheng Capital Management II (Cayman), LLC	Interest in controlled corporation[5]	[**REDACTED**]	[**REDACTED**]
Dr. Xiangmin Cui	Interest in controlled corporation[5]	[**REDACTED**]	[**REDACTED**]
Dr. Yajun Xu	Beneficial owner	[**REDACTED**]	[**REDACTED**]

Notes:

1. All interests stated are long positions.

2. Sanaron is owned as to 45.12% by Dr. Wu and 54.88% by Radiant Harbour, which is wholly owned by Trident Trust Company (HK) Limited, being the trustee of the JW Star Trust, a discretionary trust established by Dr. Wu for the benefit of his family members, and of which Dr. Wu is the settlor and Ms. Jin, the spouse of Dr. Wu, is the power holder. By virtue of the SFO, each of Radiant Harbour, Trident Trust Company (HK) Limited, Dr. Wu and Ms. Jin is deemed to be interested in the Shares in which Sanaron is interested.

3. Representing the Shares underlying the options granted to Dr. Wu under the [**REDACTED**] ESOPs. Ms. Jin is the spouse of Mr. Wu, Ms. By virtue of the SFO, Ms. Jin is deemed to be interested in the Shares in which Dr. Wu is interested.

4. FIIF, a limited partnership established in the PRC, is managed by its general partner, SDICFUND Management Co., Ltd. (國投創新投資管理有限公司) ("**SDICFUND**"). SDICFUND is 40% owned by China State Investment High-Tech Industrial Investment Co., Ltd. (中國國投高新產業投資有限公司), which in turn is controlled by State Development and Investment Corporation (國家開發投資集團有限公司), a state-owned enterprise. As such, under the SFO, each of State Development and Investment Corporation, China State Investment High-Tech Industrial Investment Co., Ltd. and SDICFUND is deemed to be interested in Shares held by FIIF.

5. Decheng Capital Management II (Cayman), LLC is the general partner of Decheng Capital China Life Sciences USD Fund II, L.P. and is wholly owned by Dr. Cui Xiangmin. By virtue of the SFO, each of Decheng Capital Management II (Cayman), LLC and Dr. Cui Xiangmin is deemed to be interested in the Shares in which Decheng Capital China Life Sciences USD Fund II, L.P. is interested.

Except as disclosed above, our Directors are not aware of any other person who will, immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised and no Shares will be issued under the ESOPs), have any interest and/or short positions in the Shares or underlying Shares of our Company which would fall to be disclosed to us and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who are, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company.